Optimisation of patient-reported outcome measurement for haematological cancer patients receiving novel immunotherapies: perspectives of multi-stakeholders
By
Eilidh M Duncan
Jhulia Salviano
Charalampia Kyriakou
Samantha Nier
Simone Oerlemans
Sam Salek
Kate Morgan
Katie Joyner
May 4, 2026
Clinical Scorecard: Enhancing Patient-Reported Outcome Measures for Hematological Cancer Patients Undergoing Innovative Immunotherapies: Insights from Multiple Stakeholders
At a Glance
Category Detail
Condition Key Mechanisms Target Population Patients with myeloma, lymphoma, and leukaemia undergoing CAR-T and BsAbs therapies. Care Setting
Key Highlights
Regulatory bodies emphasize the importance of patient-focused clinical outcome assessments. Guideline-Based Recommendations
Diagnosis
Utilize PROMs to capture treatment-related side effects and patient experiences. Develop specific PROMs for CAR-T and BsAbs therapies. Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
PROMs have been underutilized in CAR-T trials, with only 27% incorporating them, highlighting a gap in understanding patient experiences.
Clinical Best Practices
Adopt fit-for-purpose PROMs tailored to the specific experiences of patients undergoing CAR-T and BsAbs therapies. Ensure comprehensive reporting of PRO findings to inform treatment evaluations. Collaborate with stakeholders to develop tailored PROMs. References
